Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind).

NCT01056341 is registered in ClinicalTrials.gov with Pierre Fabre Dermatology as lead sponsor.

NCT NCT01056341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01056341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind).
Lead sponsor
Pierre Fabre Dermatology
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2010
Completion date
November 30, 2013
Enrollment
512 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

infantile hemangioma